8-K: Sanara MedTech Reports Q2 2026 Results, Acquisition Pending

Sanara MedTech announced a 9% revenue increase for Q2 2026 to $28.1 million, alongside a pending acquisition by MiMedx.

Summary

• Sanara MedTech reported a 9% increase in net revenue for the second quarter of 2026, reaching $28.1 million, up from $25.8 million in the prior year's quarter.
• Gross profit rose by 10% to $26.2 million, with gross margin improving to 93% from 92%.
• Operating income decreased to $1.8 million from $2.5 million in Q2 2025.
• The company reported a net loss from continuing operations of $0.4 million ($0.05 per diluted share) for Q2 2026, compared to a net income of $0.5 million ($0.05 per diluted share) in Q2 2025.
• Adjusted EBITDA increased to $5.0 million from $4.7 million in Q2 2025.
• For the first six months of 2026, net revenue increased by 14% to $55.9 million, and Adjusted EBITDA grew to $9.3 million from $7.4 million in the same period of 2025.
• The company announced a pending acquisition by MiMedx, which is expected to create a leading regenerative medicine company.
• Cash and cash equivalents stood at $15.4 million, with $46.5 million in long-term debt as of June 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but cautiously optimistic report, with strong revenue growth and improved gross margins offset by a net loss and increased operating expenses. The pending acquisition by MiMedx introduces significant future uncertainty.

Positives

• Net revenue increased by 9% to $28.1 million in Q2 2026 compared to Q2 2025.
• Gross profit increased by 10% to $26.2 million in Q2 2026.
• Gross margin improved to 93% in Q2 2026 from 92% in Q2 2025.
• Adjusted EBITDA increased to $5.0 million in Q2 2026 from $4.7 million in Q2 2025.
• Net revenue for the first six months of 2026 increased by 14% to $55.9 million.
• Adjusted EBITDA for the first six months of 2026 increased to $9.3 million from $7.4 million in the prior year.
• Net loss from discontinued operations significantly decreased to $41,720 in Q2 2026 from $2.5 million in Q2 2025.
• Net income from discontinued operations for the first six months of 2026 was $19,196, compared to a net loss of $5.4 million in the prior year.

Negatives

• Operating income decreased to $1.8 million in Q2 2026 from $2.5 million in Q2 2025.
• The company reported a net loss from continuing operations of $0.4 million ($0.05 per diluted share) in Q2 2026, a shift from a net income of $0.5 million in Q2 2025.
• Operating expenses increased by 14% year-over-year in Q2 2026, primarily due to higher SG&A and R&D.
• Other expense increased in Q2 2026 due to higher interest expense and share of losses from equity method investments.
• Cash and cash equivalents decreased to $15.4 million as of June 30, 2026, from $16.6 million as of December 31, 2025.
• Net cash used in operating activities was $0.4 million in the first six months of 2026, compared to net cash provided by operating activities of $0.7 million in the prior year.

Risks

• Uncertainties regarding the timing and completion of the proposed acquisition by MiMedx.
• Potential failure to obtain necessary governmental or regulatory approvals for the transaction.
• Risk that announcements related to the proposed transaction could negatively impact the market price of Sanara's stock.
• Disruption from the proposed transaction may make it difficult to maintain business and operational relationships.
• Risk of litigation and/or regulatory actions related to the proposed transaction.
• Uncertainties associated with the development and regulatory approval process for new products.
• Market and customer acceptance of new products.
• The effect of economic conditions, competition, and pricing on future performance.

Future Outlook

The company's future outlook is heavily influenced by the pending acquisition by MiMedx. Management is focused on continuing to meet customer needs and expanding the penetration of its surgical product portfolio, including the planned introduction of OsStic in the first quarter of 2027. The combination with MiMedx is expected to create a leading regenerative medicine company.

Management Comments

• "We continued to drive solid revenue growth in the second quarter of 2026 with net revenue of $28.1 million, representing a 9% increase over the second quarter of 2025, as well as gross margin of 93% supporting Adjusted EBITDA of $5.0 million."
• "Subsequent to the close of the quarter, we announced our entry into a transformational agreement in which Sanara is expected to be acquired by MIMEDX, a leading provider of products for applications in wound care, burn and surgical sectors of healthcare."
• "The transaction is expected to combine Sanaras pure play surgical focus and innovative technologies across collagen particulate, wound irrigation and bone fixation with MIMEDXs high-growth, best-in-class surgical portfolio, creating a leading regenerative medicine company across numerous surgical subspecialties."
• "We remain focused on continuing to meet the needs of our customers and expanding penetration of our portfolio of surgical products, which include our leading product CellerateRX Surgical, BIASURGE and OsStic, a licensed synthetic injectable structural bio-adhesive bone void filler which remains on track to be introduced to the market in the first quarter of 2027."

Industry Context

StockSavvy.ai notes that Sanara MedTech operates in the competitive medical technology sector, specifically focusing on surgical applications. The pending acquisition by MiMedx, a larger player in wound care and surgical sectors, signals consolidation trends within the regenerative medicine and surgical solutions market, aiming to create a more comprehensive entity with broader product offerings and market reach.

Stakeholder Impact

• Shareholders: The pending acquisition by MiMedx will result in shareholders receiving consideration as outlined in the merger agreement, subject to closing conditions. The market price of Sanara's stock may be affected by the transaction announcements.
• Employees: The acquisition may lead to integration of teams and potential restructuring, impacting employment. Management's attention may be diverted from ongoing business operations.
• Customers: Continued focus on meeting customer needs is stated, but integration with MiMedx could lead to changes in product offerings or service delivery.
• Creditors: The company's debt levels remain significant ($46.5 million), and the acquisition terms will dictate how these obligations are handled.

Next Steps

• Complete the acquisition by MiMedx, subject to customary closing conditions and regulatory approvals.
• Continue to meet customer needs and expand penetration of the surgical product portfolio.
• Introduce the OsStic product to the market in the first quarter of 2027.
• Integrate Sanara's technologies with MiMedx's portfolio post-acquisition.

Key Dates

Recommendation

The company shows solid revenue growth and improved gross margins, which are positive indicators. However, the shift to a net loss from continuing operations, increased operating expenses, and significant uncertainty surrounding the pending acquisition by MiMedx warrant a cautious approach. The 'hold' recommendation reflects the balance between current operational performance and the substantial unknown factors related to the acquisition's completion and future integration.

Keywords

medical technology, surgical products, regenerative medicine, wound care, bone fusion, soft tissue repair, financial results, acquisition